Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138 | Zendy

Michael M. Lederman | Zendy; Laura Smeaton | Zendy; K.Y. Smith | Zendy; Benigno Rodríguez | Zendy; Minya Pu | Zendy; Hongying Wang | Zendy; Anne Sevin | Zendy; Pablo Tebas | Zendy; Scott F. Sieg | Zendy; Kathy Medvik | Zendy; David M. Margolis | Zendy; Richard B. Pollard | Zendy; Hildegund C.J. Ertl | Zendy; Hernán Valdez | Zendy

Open Access

Cyclosporin A Provides No Sustained Immunologic Benefit to Persons with Chronic HIV‐1 Infection Starting Suppressive Antiretroviral Therapy: Results of a Randomized, Controlled Trial of the AIDS Clinical Trials Group A5138

Author(s) -

Michael M. Lederman,

Laura Smeaton,

K.Y. Smith,

Benigno Rodríguez,

Minya Pu,

Hongying Wang,

Anne Sevin,

Pablo Tebas,

Scott F. Sieg,

Kathy Medvik,

David M. Margolis,

Richard B. Pollard,

Hildegund C.J. Ertl,

Hernán Valdez

Publication year - 2006

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1086/509261

Subject(s) - immunology , medicine , immune system , clinical trial , randomized controlled trial , regimen , maraviroc , immunopathology , chronic infection , human immunodeficiency virus (hiv)

Although the determinants of immune deficiency and immune restoration in chronic human immunodeficiency virus (HIV)-1 infection are not well understood, immune activation has been proposed as being central to the pathogenesis of HIV.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research